Transarterial chemoembolization (TACE) is currently the most common approach for the management of hepatocellular carcinoma (HCC) without curative options. TACE consists of the injection of ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Resistance to immune checkpoint blockade (ICB) is a challenge in hepatocellular carcinoma therapy. Here, the authors show that targeting PRMT3 markedly improves the anticancer efficacy of ICB via ...
You will be able to get a quick price and instant permission to reuse the content in many different ways. This document, on the diagnosis and treatment of patients with hepatocellular carcinoma (HCC), ...
Foscenvivint is under clinical development by Eisai and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase ...